ArticleJournal of ovarian research2026
Taxifolin protects ovarian tissue from methotrexate-induced injury by targeting TGF-β/BMP-7 pathways.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the protective effect of taxifolin on methotrexate (MTX)-induced ovarian toxicity in a rat model. Given the increasing clinical use of MTX and its known detrimental effects on ovarian function, identifying effective protective strategies is crucial for fertility preservation. Taxifolin, a potent natural antioxidant, was investigated for its potential to mitigate oxidative damage and maintain follicular integrity. MATERIALS AND
methodsThirty adult female Wistar albino rats were randomly assigned to three groups (n = 10 each): Control, MTX, and MTX + Taxifolin. Ovarian injury was induced via a single intraperitoneal injection of MTX (20 mg/kg). The Taxifolin group received 50 mg/kg/day of taxifolin by oral gavage for 21 days post-MTX administration. Plasma malondialdehyde (MDA), anti-Müllerian hormone (AMH), and tumor necrosis factor-alpha (TNF-α) levels were assessed by ELISA. Ovarian tissue levels of bone morphogenetic protein-7 (BMP-7) and transforming growth factor-beta (TGF-β) were measured, and histopathological evaluations of follicle counts and stromal fibrosis were performed.
resultsPrimordial (p < 0.001), primary (p = 0.001), secondary (p < 0.001), and tertiary (p < 0.001) follicle counts were significantly reduced in the MTX group compared to controls but improved with taxifolin treatment (p < 0.01 or p < 0.001). Ovarian fibrosis significantly increased with MTX (p < 0.001) and was attenuated by taxifolin (p < 0.001). Biochemically, MTX elevated plasma MDA (p < 0.001) and TNF-α (p < 0.001) levels and reduced AMH (p < 0.001) and BMP-7 (p < 0.001) while increasing TGF-β (p < 0.001). Taxifolin significantly reversed these biochemical alterations (p < 0.01 or p < 0.001).
conclusionTaxifolin mitigates MTX-induced ovarian damage by reducing oxidative stress, inflammation, and fibrosis while preserving follicular development. These findings suggest taxifolin as a potential therapeutic agent for protecting ovarian function during MTX therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.